CDK4 and breast cancer: In this regard, the ESO–ESMO International Consensus for Advanced Breast Cancer provides accurate definitions, by distinguishing between primary and secondary (acquired) endocrine resistances.11 Pivotal trials that tested CDK4/6-Is in mBC have been conducted both within endocrine-sensitive and endocrine-resistant setting.